Morgan Stanley Maintains Equal-Weight on Applied Materials, Raises Price Target to $150

Morgan Stanley analyst Joseph Moore maintains Applied Materials (NASDAQ:AMAT) with a Equal-Weight and raises the price target from $139 to $150.

byBenzinga Newsdesk

August 20, 2021

1 minute read

Morgan Stanley analyst Joseph Moore maintains Applied Materials (NASDAQ:AMAT) with a Equal-Weight and raises the price target from $139 to $150.

Morgan Stanley Maintains Overweight on AES, Lowers Price Target to $29

By Benzinga Newsdesk

Today, 3:01 AM

Morgan Stanley maintains AES (NYSE:AES) with a Overweight and lowers the price target from $32.5 to $29.

AES

FDA
News

SELLAS Life Sciences Launches Expanded Access Program For Galinpepimut-S

By Benzinga Newsdesk

Today, 3:01 AM

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of

SLS

NANOBIOTIX Late Sunday Highlighted Presentation Of Phase 1 Expansion Data Evaluating Nbtxr3 As Single Agent Activated By Radiotherapy At Annual Meeting of the American Society for Radiation Oncology

By Benzinga Newsdesk

Today, 3:01 AM

Data presented by Professor Christophe Le Tourneau at the 2021 Annual Meeting of the American Society for Radiation Oncology First survival data from Phase I Dose Expansion in tough-to-treat elderly and frail LA-HNSCC

NBTX

Superior Drilling Q2 Sales $4.54M Beat $4.13M Estimate

By Bill Haddad

Today, 3:01 AM

Superior Drilling (AMEX:SDPI) reported quarterly sales of $4.54 million which beat the analyst consensus estimate of $4.13 million by 9.95 percent. This is a 33.60 percent increase over sales of $3.40 million the same

SDPI

Morgan Stanley Maintains Equal-Weight on Applied Materials, Raises Price Target to $150

Related Posts

Morgan Stanley Maintains Overweight on AES, Lowers Price Target to $29

SELLAS Life Sciences Launches Expanded Access Program For Galinpepimut-S

NANOBIOTIX Late Sunday Highlighted Presentation Of Phase 1 Expansion Data Evaluating Nbtxr3 As Single Agent Activated By Radiotherapy At Annual Meeting of the American Society for Radiation Oncology

Superior Drilling Q2 Sales $4.54M Beat $4.13M Estimate